Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Should You Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $17.89, but opened at $16.83. Daiichi Sankyo shares last traded at $16.66, with a volume of 2,134 shares traded.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Daiichi Sankyo presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The stock has a market cap of $30.79 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.90 and a beta of -0.11. The firm has a 50 day moving average of $17.82 and a two-hundred day moving average of $17.79. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.